

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4106268

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS VACCINES AND DIAGNOSTICS SRL	10/20/2016
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	11800090
Application Number:	12589218
CORRESPONDENCE DATA	
Fax Number:	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6102706812
Email:	us_cipkop@gsk.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	VN51370
NAME OF SUBMITTER:	CARLY MORROW
SIGNATURE:	/Carly Morrow/
DATE SIGNED:	10/20/2016
Total Attachments: 2	
source=VN51370 GEN Confirmatory Assignment#page1.tif	
source=VN51370 GEN Confirmatory Assignment#page2.tif	

CONFIRMATORY ASSIGNMENT

WE, GSK VACCINES S R L (formerly known as NOVARTIS VACCINES AND DIAGNOSTICS S R L) a company incorporated under the laws of Italy, having its registered office at Via Fiorentina 1, 53100, Siena, Italy, and Novartis AG a company limited by shares duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby declare that we are or were the sole owner of the following patents/applications listed in the attached Schedule 1, entitled **Conserved Neisserial Antigens**


And in accordance with the Patent Assignment Agreement dated 26 February 2015 between Novartis Vaccines and Diagnostics S r l , Novartis Pharma AG and Novartis AG, NOVARTIS VACCINES AND DIAGNOSTICS S R L has assigned and GSK VACCINES S R L hereby assigns the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/these application(s) are filed to Novartis AG

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between NOVARTIS AG and GLAXOSMITHKLINE BIOLOGICALS SA for good and valuable consideration, the receipt of which is hereby acknowledged, we NOVARTIS AG have assigned and hereby assign the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/these application(s) are filed to GLAXOSMITHKLINE BIOLOGICALS SA of Rue de l'Institut 89, 1330 Rixensart, Belgium

NOVARTIS VACCINES AND DIAGNOSTICS S R L has changed its name, as of 1 September 2015, into the new name "GLAXOSMITHKLINE VACCINES S R L " or in abbreviated form "GSK VACCINES S R L "


Dated this 20 October 2016

Signed for and on behalf of GSK VACCINES S R L




 Lorraine B. Ling
 Authorized Signatory on behalf of GSK VACCINES S R L

Signed for and on behalf of NOVARTIS AG




 William R. Majarian
 Authorized Signatory on behalf of
 NOVARTIS AG



 Theodore R. Furman
 Authorized Signatory on behalf of
 NOVARTIS AG

Signed for and on behalf of GLAXOSMITHKLINE BIOLOGICALS SA



 Edward R. Gimmi
 Authorized Official on behalf of GLAXOSMITHKLINE BIOLOGICALS SA

Country	Application Date	Schedule 1		Patent Number
		Application Number	Grant Date	
Australia	21-Nov-08	2008249139		
Austria	26-Sep-10	10179801 5	16-Apr-14	EP2278007
Austria	27-Sep-10	10180438 3	20-Aug-14	EP2290083
Canada	28-Apr-00	2372235		
China P R	17-Apr-08	200810092797 7	12-Aug-15	ZL200810092797 7
China P R				
European Patent Convention	27-Sep-10	10180438 3	20-Aug-14	EP2290083
European Patent Convention	28-Apr-00	00922818 0	21-Nov-12	EP1228217
European Patent Convention	26-Sep-10	10179801 5	16-Apr-14	EP2278007
France	26-Sep-10	10179801 5	16-Apr-14	EP2278007
France	27-Sep-10	10180438 3	20-Aug-14	EP2290083
United Kingdom	27-Sep-10	10180438 3	20-Aug-14	EP2290083
United Kingdom	26-Sep-10	10179801 5	16-Apr-14	EP2278007
Germany	26-Sep-10	10179801 5	16-Apr-14	60048526 9
Germany	27-Sep-10	10180438 3	20-Aug-14	60048702 4
Italy	27-Sep-10	502014000001938	20-Aug-14	EP2290083
Italy	26-Sep-10	502014902274823	16-Apr-14	EP2278007
Japan	13-Jun-13	2013-124476		
Mexico	20-Aug-09	MX/a/2009/008901	01-Jun-12	299790
Mexico	30-May-12	MX/a/2012/006225	16-Dec-15	335727
Switzerland	26-Sep-10	10179801 5	16-Apr-14	EP2278007
Switzerland	27-Sep-10	10180438 3	20-Aug-14	EP2290083
Spain	27-Sep-10	10180438 3	20-Aug-14	EP2290083
Spain	26-Sep-10	10179801 5	16-Apr-14	EP2278007
United States	02-May-07	11/800090	20-Oct-09	7604810
United States	19-Oct-09	12/589218	27-Oct-15	9169301